Kadderum (Eltrombopag)

Eltrombopag acts on the thrombopoietin pathway to increase platelet production in several hematologic conditions.

• Chronic immune thrombocytopenia (ITP): raises platelet counts in patients with persistent low platelets.
• Severe aplastic anemia: supports platelet generation as part of broader marrow recovery.
• Hepatitis C‑related thrombocytopenia: improves platelet levels to enable antiviral therapy.

• Eltrombopag binds to the thrombopoietin receptor (c‑Mpl) on megakaryocyte precursors, activating intracellular signaling cascades that promote megakaryocyte proliferation and differentiation, ultimately increasing platelet production without requiring endogenous thrombopoietin.

Eltrombopag may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools that may be transient.
• Headache: mild tension‑type pain.
• Fatigue: general tiredness.
• Elevated liver enzymes: mild transaminase rise.
• Dyspepsia: indigestion or upper abdominal discomfort.

Serious or Rare Side Effects

• Thromboembolic events: clot formation in veins or arteries.
• Severe liver injury: marked elevation of hepatic enzymes or hepatitis.
• Worsening aplastic anemia: further suppression of bone‑marrow function.
• Severe neutropenia: marked reduction in neutrophil count.
• Cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Retinal pigment changes: visual disturbances requiring ophthalmic review.

Before initiating therapy, clinicians should evaluate baseline parameters and monitor patients regularly.

• Liver function monitoring: check transaminases before and during treatment.
• Hematologic surveillance: perform complete blood counts periodically.
• Avoid in active thrombosis: contraindicated in patients with recent clotting events.
• Pregnancy caution: safety not established; weigh benefits against risks.
• Drug interaction vigilance: review concomitant CYP3A4 inducers or inhibitors.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Eltrombopag can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce exposure.
• Antacids containing polyvalent cations (e.g., calcium, magnesium): impair oral absorption.
• Warfarin: may increase INR and bleeding risk.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., ketoconazole, fluconazole): increase plasma levels.
• Oral contraceptives: potential reduction in contraceptive effectiveness.
• Other myelosuppressive agents: additive bone‑marrow suppression.
• Statins metabolized by CYP3A4: monitor for increased statin exposure.